<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0805257362
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEGACEF 1GM VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTAZIDIME
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Negacef</strong> is an antibiotic used in adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.</p><p><strong>Negacef is used to treat severe bacterial infections of: </strong></p><p>- the lungs or chest</p><p>- the lungs and bronchi in patients suffering from cystic fibrosis</p><p>- the brain (meningitis)</p><p>- the ear</p><p>- the urinary tract</p><p>- the skin and soft tissues</p><p>- the abdomen and abdominal wall (peritonitis)</p><p>- the bones and joints.</p><p><strong>Negacef</strong> can also be used:</p><p>-&nbsp; to prevent infections during prostate surgery in men</p><p>-&nbsp; to treat patients with low white blood cell counts (neutropenia) who have a fever due to a bacterial infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Negacef: </strong></p><p>-&nbsp; if <strong>you are allergic</strong> to <strong>ceftazidime </strong>or any of the other ingredients of this medicine (listed in section no. 6).</p><p>-&nbsp; if you have had a <strong>severe allergic reaction </strong>to any<strong> other antibiotic </strong>(penicillins, monobactams and carbapenems) as you may also be allergic to <strong>Negacef</strong>.</p><p><strong>Tell your doctor before </strong>you start on <strong>Negacef</strong> if you think that this applies to you. You must not be given <strong>Negacef</strong>.</p><p><strong>Take special care with Negacef </strong></p><p>You must look out for certain symptoms such as allergic reactions, nervous system disorders and gastrointestinal disorders such as diarrhoea while you are being given <strong>Negacef</strong>. This will reduce the risk of possible problems. See (&lsquo;Conditions you need to look out for&rsquo;) in section 4. If you have had an allergic reaction to other antibiotics you may also be allergic to <strong>Negacef</strong>.</p><p><strong>If you need a blood or urine test </strong></p><p><strong>Negacef</strong> can affect the results of urine tests for sugar and a blood test known as the Coombs test. If you are having tests:</p><p><strong>Tell the person taking the sample </strong>that you have been given <strong>Negacef</strong>.</p><p><strong>Other medicines and Negacef </strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. This includes medicines you can obtain without a prescription.</p><p>You shouldn&rsquo;t be given <strong>Negacef</strong> without talking to your doctor if you are also taking:</p><p>-&nbsp; An antibiotic called chloramphenicol<em> </em></p><p>-&nbsp; A type of antibiotic called aminoglycosides e.g. gentamicin, tobramycin<em> </em></p><p>-&nbsp; Water tablets called furosemide</p><p><strong>Tell your doctor </strong>if this applies to you.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>Ask your doctor for advice before you are given <strong>Negacef</strong>:</p><p>-&nbsp; If you are pregnant, think you might be pregnant or are planning to become pregnant</p><p>-&nbsp; If you are breast-feeding</p><p>Your doctor will consider the benefit of treating you with <strong>Negacef</strong> against the risk to your baby.</p><p><strong>Driving and using machines </strong></p><p><strong>Negacef</strong> can cause side effects that affect your ability to drive, such as dizziness. Don&rsquo;t drive or use machines unless you are sure you&rsquo;re not affected.</p><p><strong>Negacef contains sodium </strong></p><p>You need to take this into account if you are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Negacef is usually given by a doctor or nurse</strong>. It can be given as a <strong>drip </strong>(intravenous infusion) or as an <strong>injection </strong>directly into a vein or into a muscle.</p><p><strong>Negacef</strong> is made up by the doctor, pharmacist or nurse using water for injections or a suitable infusion fluid.</p><p><strong>The recommended dose </strong></p><p>The correct dose of <strong>Negacef</strong> for you will be decided by your doctor and depends on: the severity and type of infection; whether you are on any other antibiotics; your weight and age; how well your kidneys are working.</p><p><strong>Newborn babies (0-2 months) </strong></p><p>For every 1kg the baby weighs,<strong> </strong>they will be given 25 to 60mg <strong>Negacef</strong> per day divided in two doses.</p><p><strong>Babies (over 2 months) and children who weigh less than 40kg</strong></p><p>For every 1kg the baby or child weighs,<strong> </strong>they will be given 100 to 150mg of <strong>Negacef</strong> per day divided in three doses. Maximum 6 g per day.</p><p><strong>Adults and adolescents </strong>who weigh 40kg or more<strong> </strong></p><p>1 to 2g of <strong>Negacef</strong> three times daily. Maximum of 9g per day.</p><p><strong>Patients over 65 </strong></p><p>The daily dose should not normally exceed 3 g per day, especially if you are over 80 years of age.</p><p><strong>Patients with kidney problems </strong></p><p>You may be given a different dose to the usual dose. The doctor or nurse will decide how much <strong>Negacef</strong> you will need, depending on the severity of the kidney disease. Your doctor will check you closely and you may have more regular kidney function tests.</p><p><strong>If you are given more Negacef than you should </strong></p><p>If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p><strong>If you forget to use Negacef </strong></p><p>If you miss an injection, you should have it as soon as possible. Don&rsquo;t take a double dose (two injections at the same time) to make up for a missed dose.</p><p><strong>Don&rsquo;t stop taking Negacef </strong></p><p>Don&rsquo;t stop taking <strong>Negacef</strong> unless your doctor tells you to.</p><p><strong>If you have any further questions on the use of this product, ask your doctor, nurse or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Conditions you need to look out for </strong></p><p>The following serious side effects have occurred in a small number of people but their exact frequency is unknown:</p><p>-&nbsp; <strong>Severe allergic</strong> <strong>reaction</strong>.<strong> </strong>Signs include <strong>raised</strong> <strong>and</strong> <strong>itchy</strong> <strong>rash</strong>, <strong>swelling</strong>, sometimes of the face or mouth causing <strong>difficulty</strong> <strong>in</strong> <strong>breathing</strong>.</p><p>-&nbsp; <strong>Skin</strong> <strong>rash</strong>, which may <strong>blister</strong>, and looks like <strong>small</strong> <strong>targets </strong>(central dark spot surrounded by a paler area, with a dark ring around the edge).</p><p>-&nbsp; A <strong>widespread</strong> <strong>rash </strong>with <strong>blisters </strong>and <strong>peeling</strong> <strong>skin</strong>.<strong> </strong>(These may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis).</p><p>-&nbsp; <strong>Nervous</strong> <strong>system</strong> <strong>disorders</strong>:<strong> </strong>tremors, fits and, in some cases coma. These have occurred in people when the dose they are given is too high, particularly in people with kidney disease.</p><p>-&nbsp; There have been rare reports of severe hypersensitivity reactions with severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung (a reaction called DRESS).</p><p><strong>Contact a doctor or nurse immediately if you get any of these symptoms. </strong></p><p><strong>Common side effects </strong></p><p>These may affect <strong>up to</strong> <strong>1</strong> <strong>in</strong> <strong>10</strong> people:</p><p>-&nbsp; Diarrhoea</p><p>-&nbsp; Swelling and redness along a vein</p><p>-&nbsp; Red raised skin rash which may be itchy</p><p>-&nbsp; Pain, burning, swelling or inflammation at the injection site.</p><p><strong>Tell your doctor </strong>if any of these are troubling you.</p><p>Common side effects that may show up in blood tests:</p><p>-&nbsp; an increase in a type of white blood cell (<em>eosinophilia) </em></p><p>-&nbsp; an increase in the number of cells that help the blood to clot</p><p>-&nbsp; an increase in liver enzymes.</p><p><strong>Uncommon side effects </strong></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>-&nbsp; inflammation of the gut which can cause pain, or diarrhoea which may contain blood</p><p>-&nbsp; thrush (fungal infections in the mouth or vagina)</p><p>-&nbsp; headache</p><p>-&nbsp; dizziness</p><p>-&nbsp; stomach ache</p><p>-&nbsp; feeling sick or being sick</p><p>-&nbsp; fever and chills.</p><p><strong>Tell your doctor </strong>if you get any of these.</p><p>Uncommon side effects that may show up in blood tests:</p><p>-&nbsp; a decrease in the number of white blood cells</p><p>-&nbsp; a decrease in the number of blood platelets (cells that help the blood to clot)</p><p>-&nbsp; an increase in the level of urea, urea nitrogen or serum creatinine in the blood.</p><p><strong>Very rare side effects </strong></p><p>These may affect <strong>up to 1 in 10,000 </strong>people:</p><p>-&nbsp; inflammation or failure of the kidneys</p><p><strong>Other side effects </strong></p><p>Other side effects have occurred in a small number of people but their exact frequency is unknown:</p><p>-&nbsp; pins and needles</p><p>-&nbsp; unpleasant taste in the mouth</p><p>-&nbsp; yellowing of the whites of the eyes or skin.</p><p>Other side effects that may show up in blood tests:</p><p>-&nbsp; red blood cells destroyed too quickly</p><p>-&nbsp; an increase in a certain type of white blood cells</p><p>-&nbsp; severe decrease in the number of white blood cells.</p><p><strong>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. </strong></p><p><strong><u>To report any side effect(s)</u></strong><strong><u>: </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax: </strong>+966-11-205-7662</p><p><strong>Call NPC at +966-11-2038222, Exts: </strong>2317-2356-2353-2354-2334-2340<strong>.</strong></p><p><strong>Toll free phone: 8002490000</strong></p><p><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>Website: </strong>www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Negacef</strong> is for use in hospital only and the expiry date and storage instructions stated on the inner label and carton are for the doctor, nurse or pharmacist&#39;s information. The doctor or nurse will make up your medicine.</p><p>-&nbsp;&nbsp; Do not use <strong>Negacef</strong> after the expiry date which is stated on the carton and on the inner label.</p><p>-&nbsp;&nbsp; <strong>Before reconstitution</strong>, store below 30&deg;C. Protect from light and heat.</p><p><strong>&nbsp;&nbsp; After reconstitution, see below &ldquo;</strong><strong>Stability after reconstitution&rdquo;.</strong></p><p>-&nbsp;&nbsp; <strong>Do</strong> not use <strong>Negacef</strong> if you notice any visible sign of deterioration.</p><p>-&nbsp; &nbsp;Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose off&nbsp;&nbsp; &nbsp;&nbsp;medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ceftazidime. Each vial contains ceftazidime pentahydrate (USP) equivalent to ceftazidime 0.5 g,<br />1 g or 2 g and sodium carbonate approximately equivalent to 60mg, 121mg or 242mg, respectively.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Negacef sterile powder for injection is available as follows (not all presentations are available in all countries):  
Negacef 0.5g IM/IV: Pack of 1 vial.
Negacef 1g IM/IV:    Pack of 1 or 10 vials.
Negacef 1g IM:        Pack of 1 vial and 1 solvent ampoule of 3mL lidocaine HCl 1%. 
Negacef 1g IV:        Pack of 1 vial and 1 solvent ampoule of 10mL sterile water for injection.
Negacef 2g IV:        Pack of 1 vial.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
08/02/2015

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>نيجاسيف</strong> هو عبارة عن مضاد حيوي يُستعمل للبالغين والأطفال (بما في ذلك الأطفال حديثي الولادة). وهو يعمل عن طريق القضاء على البكتيريا التي تسبب العدوى. وينتمي إلى مجموعة الأدوية التي تعرف باسم السيفالوسبورينات.</p><p dir="RTL"><strong>يُستعمل نيجاسيف لعلاج العدوى البكتيرية الشديدة التي تصيب:</strong></p><p dir="RTL">-&nbsp; الرئتين أو الصدر</p><p dir="RTL">-&nbsp; الرئتين والشعب الهوائية لدى المرضى الذين يعانون من تليف كيسي</p><p dir="RTL">-&nbsp; الدماغ (التهاب السحايا)</p><p dir="RTL">-&nbsp; الأذن</p><p dir="RTL">-&nbsp; الجهاز البولية</p><p dir="RTL">-&nbsp; الجلد والأنسجة الرخوة</p><p dir="RTL">-&nbsp; البطن وجدار البطن (التهاب البريتون)</p><p dir="RTL">-&nbsp; العظام والمفاصل</p><p dir="RTL">كما يمكن استعمال<strong> نيجاسيف</strong> في الحالات التالية:</p><p dir="RTL">-&nbsp; للوقاية من العدوى خلال عمليات جراحة البروستات لدى الرجال</p><p dir="RTL">-&nbsp; لعلاج المرضى الذين يعانون من من نقص تعداد خلايا الدم البيضاء (نقص الكريات المتعادلة) ويعانون من الحمى الناجمة عن العدوى البكتيرية.</p><p dir="RTL"><strong>2.&nbsp; ما عليك معرفته قبل أن يتم إعطائك نيجاسيف&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عدم إعطائك نيجاسيف في الحالات التالية:</strong></p><p dir="RTL"><strong>يجب عدم إعطائك نيجاسيف في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp; إذا كنت <strong>تعاني من الحساسية</strong> تجاه <strong>سيفتازديم</strong>، أو أياً من المكونات الأخرى في هذا الدواء (المذكورة في الفقرة &nbsp;رقم 6).</p><p dir="RTL">-&nbsp;&nbsp; إذا عانيت مسبقاً من <strong>تفاعل</strong> <strong>تحسسي</strong> <strong>شديد</strong> تجاه أياً من <strong>المضادات</strong> <strong>الحيوية</strong> الأخرى (بنسيلينات، مونوباكتام وكاربابينيم)، ققد تعاني أيضاً من الحساسية تجاه <strong>نيجاسيف</strong>.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج </strong>قبل البدء في استعمال <strong>نيجاسيف</strong>، إذا كنت تعتقد أن أياً مما ذكر أعلاه ينطبق عليك، ففي هذه الحالة يجب عدم إعطائك <strong>نيجاسيف</strong>.</p><p dir="RTL"><strong>تحذيرات خاصة قبل استعمال نيجاسيف</strong></p><p dir="RTL">-&nbsp;&nbsp; يُرجى الانتباه ورصد بعض الأعراض المعينة التي قد تحدث على سبيل المثال التفاعلات التحسسية، اضطرابات في الجهاز العصبي واضطرابات في الجهاز الهضمي على سبيل المثال الإسهال أثناء استعمال<strong> نيجاسيف</strong>. سوف يقلل ذلك من خطر حدوث الاضطرابات المحتملة. انظر (&rsquo;حالات تتطلب اليقظة والانتباه‛) في الفقرة رقم 4. إذا عانيت مسبقاً من التفاعلات التحسسية تجاه أياً من المضادات الحيوية الأخرى، ققد تعاني أيضاً من الحساسية تجاه <strong>نيجاسيف</strong>.</p><p dir="RTL"><strong>إذا ما كنت تحتاج لإجراء فحوصات للدم أو البول</strong></p><p dir="RTL">قد يؤثر <strong>نيجاسيف</strong> على نتائج فحوصات البول لقياس السكر وكذلك على فحص للدم يعرف باختبار كومب. لذا إذا كنت ستخضع لإجراء فحوصات معينة:</p><p dir="RTL"><strong>يرجى منك إخبار الشخص</strong> <strong>الذي سيقوم بأخذ العينة</strong> أنك تستعمل <strong>نيجاسيف</strong>.</p><p dir="RTL"><strong>استعمال الأدوية الأخرى بالت</strong><strong>زامن مع </strong><strong>نيجاسيف</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية.</p><p dir="RTL">يجب ألا يتم إعطاؤك<strong> نيجاسيف</strong> دون إخبار طبيبك المعالج، إذا كنت تستعمل بالتزامن أياً من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp; مضاداً حيوياً يعرف باسم كلورامفينيكول</p><p dir="RTL">-&nbsp;&nbsp; نوع من المضادات الحيوية يعرف باسم أمينوجلايكوسيدات على سبيل المثال جنتامايسين، توبرامايسين.</p><p dir="RTL">-&nbsp;&nbsp; أقراص مدرة للبول تعرف باسم فيوروسيمايد.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج</strong>، إذا كان أياً مما ذكر أعلاه ينطبق عليك.</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية والخصوبة </strong></p><p dir="RTL">استشيري طبيبك المعالج قبل استعمال <strong>نيجاسيف</strong> في الحالات التالية:</p><p dir="RTL">-&nbsp; إذا كنت حاملاً أو تعتقدين بأنك كذلك، أو تخططين لكي تصبحين حاملاً</p><p dir="RTL">-&nbsp; إذا كنت ترضعين طفلك رضاعة طبيعية</p><p dir="RTL">سوف يأخذ طبيب بالمعالج بعين الاعتبار الفوائد المرجوة من العلاج مع <strong>نيجاسيف</strong> مقارنةً بأضراره التي قد تكون خطراً على طفلك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب <strong>نيجاسيف</strong> تأثيرات جانبية تؤثر على قدرتك على القيادة على سبيل المثال الدوخة. يُنصح بعدم القيادة أو <strong>استخدام </strong>الآلات إلا إذا كنت متأكداً أنك لا تعاني من أية تأثيرات سلبية.</p><p dir="RTL"><strong>يحتوي نيجاسيف على الصوديوم</strong></p><p dir="RTL">يجب أخذ ذلك بعين الاعتبار في حال كنت تتبع حمية غذائية محدودة الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>عادةً يتم إعطاء نيجاسيف من قبل الطبيب المعالج أو الممرض</strong>.<strong>&nbsp;</strong></p><p dir="RTL"><strong>عادةً يتم إعطاء نيجاسيف من قبل الطبيب المعالج أو الممرض</strong>.<strong> </strong>ويمكن<strong> </strong>إعطاؤه <strong>بالتنقيط</strong> الوريدي (التسريب الوريدي) أو <strong>بالحقن</strong> مباشرةً في الوريد أو في العضل.</p><p dir="RTL">سوف يقوم الطبيب، الصيدلي أو الممرض بتحضير <strong>نيجاسيف</strong> باستعمال ماء معد للحقن أو أياً من السوائل المناسبة المستخدمة للتسريب الوريدي.</p><p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">سوف يقوم الطبيب المعالج بتقدير الجرعة الصحيحة من <strong>نيجاسيف </strong>وذلك اعتماداً على: نوع العدوى ومدى شدتها، إذا كنت تتناول أية مضادات حيوية أخرى، الوزن والعمر، وكذلك مدى كفاءة وظيفة الكلى.</p><p dir="RTL"><strong>الأطفال حديثي الولادة (بعمر يصل إلى شهرين)</strong></p><p dir="RTL">يتم إعطاء <strong>نيجاسيف </strong>بمقدار يترواح من 25 ملغم إلى 60 ملغم لكل كيلوغرام واحد من وزن الطفل في اليوم مقسمة على جرعتين.</p><p dir="RTL"><strong>الأطفال الرضع (أكبر من شهرين) والأطفال</strong> الذين يزنون أقل من 40 كلغم</p><p dir="RTL">يتم إعطاء <strong>نيجاسيف </strong>بمقدار يترواح من 100 ملغم إلى 150 ملغم لكل كيلوغرام واحد من وزن الطفل في اليوم مقسمة على على ثلاث جرعات.</p><p dir="RTL">يبلغ مقدار الجرعة القصوى 6 غرام في اليوم.</p><p dir="RTL"><strong>البالغون والمراهقون &nbsp;</strong>الذين يزنون 40 كلغم أو فما فوق</p><p dir="RTL">يتم إعطاء <strong>نيجاسيف </strong>بمقدار يترواح من 1 غرام إلى 2 ثلاث مرات يومياً. يبلغ مقدار الجرعة القصوى 9 غرام في اليوم.</p><p dir="RTL"><strong>المرضى بعمر أكبر من 65 سنة</strong></p><p dir="RTL">يجب عدم تجاوز مقدار الجرعة عن 3 غرام في اليوم، وبصفة خاصة لدى المرضى بعمر أكبر من 80 سنة.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكلى</strong></p><p dir="RTL">قد يتم إعطاؤك جرعة مختلفة عن الجرعة الاعتيادية. سوف يحدد الطبيب المعالج أو الممرض مقدار جرعة من <strong>نيجاسيف</strong> التي تحتاجها، وذلك اعتماداً على شدة اضطراب الكلى. سوف يقوم الطبيب المعالج بمعاينة حالتك الصحية عن كثب، كما قد يطلب منك إجراء فحوصات وظائف الكلية بصورة دورية.</p><p dir="RTL"><strong>في حال إعطائك نيجاسيف بجرعة أكبر مما يجب على سبيل الخطأ</strong></p><p dir="RTL">إذا تم إعطاؤك <strong>نيجاسيف</strong> بجرعة أكبر مما يجب على سبيل الخطأ، عندئذٍ يرجى منك الاتصال على &nbsp;طبيبك المعالج على الفور أو التوجه &nbsp;إلى أقرب مستشفى على الفور.</p><p dir="RTL"><strong>إذا سهوت عن استعمال نيجاسيف</strong></p><p dir="RTL">إذا سهوت عن استعمال حقنة من حقن <strong>نيجاسيف</strong>، فإنه يجب عليك استعمالها في أسرع وقت ممكن حال تذكرها. يجب عدم أخذ جرعتين في آنٍ واحد (حقنتين في نفس الوقت) لتعويض عن الجرعة التي قد سهوت عنها.</p><p dir="RTL"><strong>يجب عدم التوقف عن استعمال نيجاسيف</strong></p><p dir="RTL">يجب عدم التوقف عن استعمال حقن<strong> نيجاسيف </strong>ما لم يخبرك طبيبك المعالج بذلك.<strong> </strong></p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج، الممرض أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو عليه الحال مع جميع الأدوية، قد يسبب هذا الدواء حدوث تأثيرات جانبية، بالرغم من أنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>حالات تتطلب منك اليقظة والانتباه</strong></p><p dir="RTL">إن التأثيرات الجانبية الخطيرة التالية تحدث لدى فئة قليلة من المرضى، ولكن معدل تكرار حدوثها الحقيقي غير معروف:</p><p dir="RTL">-&nbsp;&nbsp; <strong>تفاعل تحسسي شديد</strong>. تتضمن علامات التي تشير إلى حدوث ذلك على <strong>طفح جلدي مرتفع عن سطح الجلد ومصحوب بحكة</strong>، تورم في بعض الأحيان للوجه أو الفم مما يؤدي إلى <strong>صعوبة في التنفس.</strong></p><p dir="RTL">-&nbsp;&nbsp; <strong>طفح جلدي</strong> قد يتطور إلى <strong>تقرحات</strong> على شكل <strong>حلقات دائرية ذات نقطة مركزية</strong> (بقعة مركزية داكنة اللون محاطة بمنطقة شاحبة اللون مع حدود داكنة اللون ذات شكل حلقي).</p><p dir="RTL">-&nbsp;&nbsp; <strong>طفح جلدي منتشر</strong> <strong>مصحوب بحدوث تقرحات وتقشر في الجلد</strong>. (قد تكون هذه علامات لحدوث متلازمة ستيفنز-جونسون أو انحلال البشرة السمي المتنخر).</p><p dir="RTL">-&nbsp;&nbsp; <strong>اضطرابات الجهاز العصبي</strong>: ارتعاش، تشنجات وفي بعض الحالات غيبوبة. وقد تم تسجيل هذه الأعراض لدى الأشخاص الذين تلقوا العلاج بجرعات مرتفعة جداً، وبصفة خاصة لدى الأشخاص الذين يعانون من اضطرابات في الكلى.</p><p dir="RTL">-&nbsp;&nbsp; لقد تم تسجيل حالات نادرة لحدوث تفاعلات فرط الحساسية الشديدة مصحوبة بطفح جلدي شديد، وقد تكون مرتبطة بحدوث حمى، شعور بالتعب، تورم الوجه أو الغدة الليمفاوية، ارتفاع مستوى الخلايا الحمضية (نوع من أنواع خلايا الدم البيضاء)، تأثيرات على الكلى، الكبد أو الرئة (تفاعل يعرف باسم التفاعلات الدوائية المصاحبة لفرط الحمضات والأعراض الجهازية )</p><p dir="RTL"><strong>يرجى منك التواصل مع الطبيب المعالج أو الممرض على الفور في حال تعرضك لأي من هذه الأعراض.</strong></p><p dir="RTL"><strong>تأثيرات جانبية شائعة </strong></p><p dir="RTL">قد تصيب <strong>ما يصل إلى</strong> <strong>شخص واحد من كل 10</strong> أشخاص:</p><p dir="RTL">-&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp; تورم واحمرار على امتداد الوريد</p><p dir="RTL">-&nbsp;&nbsp; طفح جلدي محمر ومرتفع عن سطح الجلد والذي قد يكون مصحوباً بحكة</p><p dir="RTL">-&nbsp;&nbsp; ألم، حرقة، تورم أو التهاب في موضع الحقن.</p><p dir="RTL"><strong>يرجى منك إخبار</strong> طبيبك المعالج بالأمر في حال كنت تشعر بالقلق حول أياً من هذه الأعراض.</p><p dir="RTL">قد تظهر التأثيرات الجانبية الشائعة التالية في فحوصات الدم:</p><p dir="RTL">-&nbsp; ارتفاع أحد أنواع خلايا الدم البيضاء (فرط الحمضيات)</p><p dir="RTL">-&nbsp; ارتفاع تعداد الخلايا التي تساعد على تخثر الدم</p><p dir="RTL">-&nbsp; ارتفاع مستوى إنزيمات الكبد.</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة</strong></p><p dir="RTL">قد تصيب <strong>ما يصل إلى</strong> <strong>شخص واحد من كل 100</strong> شخص:</p><p dir="RTL">-&nbsp; التهاب القناة الهضمية مما يسبب الشعور بألم، أو إسهال الذي قد يكون مصحوب بدم</p><p dir="RTL">-&nbsp; داء القلاع (عدوى فطرية تصيب الفم أو المهبل)</p><p dir="RTL">-&nbsp; صداع</p><p dir="RTL">-&nbsp; دوخة</p><p dir="RTL">-&nbsp; ألم في المعدة</p><p dir="RTL">-&nbsp; الشعور بالإعياء أو توعك</p><p dir="RTL">-&nbsp; حمى ورعشة.</p><p dir="RTL"><strong>يرجى منك إخبار</strong> طبيبك المعالج بالأمر إذا كنت تعاني أياً من هذه الأعراض.</p><p dir="RTL">قد تظهر التأثيرات الجانبية الغير شائعة التالية في فحوصات الدم:</p><p dir="RTL">-&nbsp; انخفاض تعداد خلايا الدم البيضاء</p><p dir="RTL">-&nbsp; انخفاض تعداد الصفائح الدموية (الخلايا التي تساعد على تخثر الدم)</p><p dir="RTL">-&nbsp; ارتفاع مستوى اليوريا، نتروجين اليوريا أو كرياتينين المصل في الدم.</p><p dir="RTL"><strong>تأثيرات جانبية نادرة جداً</strong></p><p dir="RTL">قد تصيب <strong>ما يصل إلى &nbsp;شخص واحد من كل 10000</strong> شخص:</p><p dir="RTL">-&nbsp; التهاب أو فشل كلوي</p><p dir="RTL"><strong>تأثيرات جانبية أخرى</strong></p><p dir="RTL">لقد حدثت تأثيرات جانبية أخرى في عدد قليل من الأشخاص ولكن معدل تكرار حدوثها الحقيقي غير معروف:</p><p dir="RTL">-&nbsp; الشعور بتنميل أو خدر (شبيه بوخز الدبابيس والإبر)</p><p dir="RTL">-&nbsp; مذاق غير مرغوب به في الفم</p><p dir="RTL">-&nbsp; اصفرار بياض العينين أو الجلد.</p><p dir="RTL">قد تظهر التأثيرات الجانبية الأخرى التالية في فحوصات الدم:</p><p dir="RTL">-&nbsp; انحلال خلايا الدم الحمراء بصورة سريعة جداً</p><p dir="RTL">-&nbsp; ارتفاع مستوى نوع معين من خلايا الدم البيضاء</p><p dir="RTL">-&nbsp; انخفاض شديد في تعداد خلايا الدم البيضاء</p><p dir="RTL"><strong>يُرجى إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض،&nbsp; في حال حدوث أية تأثيرات جانبية بما في ذلك أية تأثيرات جانبية غير مذكورة في هذه النشرة.</strong></p><p dir="RTL"><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية</u></strong><strong><u>:</u></strong></p><p dir="RTL"><strong>&nbsp;</strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL"><strong>رقم الفاكس: </strong>7662-205-11-966+</p><p dir="RTL"><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: </strong>2038222-11-966+</p><p dir="RTL"><strong>وصلة هاتف:</strong>2340-2334-2354-2353-2356-2317</p><p dir="RTL"><strong>الهاتف المجاني: 8002490000</strong></p><p dir="RTL"><strong>البريد الإلكتروني: </strong>npc.drug@sfda.gov.sa</p><p dir="RTL"><strong>الموقع الإلكتروني: </strong>www.sfda.gov.sa/npc</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن <strong>نيجاسيف</strong> معد للاستعمال داخل المسستشفى فقط، وظروف التخزين الخاصة به وتاريخ انتهاء الصلاحية المذكور على الملصق الداخلي للزجاجة والعبوة</p><p dir="RTL">&nbsp;هي معلومات تخص الطبيب والممرض والصيدلي. سيقوم الطبيب أو الممرض بتحضير الدواء وحقنه.</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم استعمال <strong>نيجاسيف</strong> بعد انتهاء تاريخ الصلاحية المذكور على العبوة وملصق الداخلي للزجاجة.</p><p dir="RTL">-&nbsp;&nbsp; <strong>قبل التحضير</strong>، يحفظ في درجة حرارة أقل من 30&deg;م، بعيداً عن الضوء والحرارة.</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; بعد التحضير</strong>، انظر أدناه <strong>&nbsp;&quot;</strong><strong>استقرار المحاليل بعد التحضير&quot;</strong>.</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم استعمال <strong>نيجاسيف</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيفتازديم. تحتوي كل زجاجة على سيفتازديم خماسي الهيدرات بما يعادل 0,5 غرام أو 1 غرام أو 2 غرام من سيفتازديم مع 60 ملغم أو 121 ملغم&nbsp; أو 242 ملغم من كربونات الصوديوم على التوالي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مسحوق <strong>نيجاسيف</strong> المعقم المعد للحقن متوفر في العبوات التالية (لا تتوفر جميع العبوات في جميع البلدان):</p><p dir="RTL"><strong>نيجاسيف </strong>0,5 غرام للحقن في العضل/في الوريد: عبوة تحتوي على زجاجة واحدة.</p><p dir="RTL"><strong>نيجاسيف </strong>1 غرام للحقن في العضل/في الوريد:&nbsp;&nbsp;&nbsp; عبوة تحتوي على 1 أو 10 زجاجات.</p><p dir="RTL"><strong>نيجاسيف </strong>1 غرام للحقن في العضل: عبوة تحتوي على زجاجة واحدة مع أمبولة مذيب واحدة سعة 3 ملليلتر من هيدروكلوريد الليدوكين 1%.</p><p dir="RTL"><strong>نيجاسيف </strong>1 غرام للحقن في الوريد: عبوة تحتوي على زجاجة واحدة مع أمبولة مذيب واحدة سعة 10 ملليلتر من الماء المعقم المعد للحقن.</p><p dir="RTL"><strong>نيجاسيف </strong>2 غرام للحقن في الوريد: عبوة تحتوي على زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
8/2/2015م

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Negacef 1g Sterile Powder for Solution for I.M. /I.V. Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Item No.	Material Name	Scale (mg/Vial)
		
	Active Ingredients:	
1.		Sterile Ceftazidime *	1240.00
	Equivalent to Ceftazidime  	1000.00
		
	Inactive Ingredients:	
1.		Sodium Carbonate 	121.00
		
*Quantity of Sterile Ceftizidime is calculated on the basis of assay of assay 95% (dried basis) and 15% moisture compensation. Quantity may vary depending on the assay of material.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile powder for solution for injection (Powder for Injection)
Description: White to slightly yellowish crystalline powder. 	


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Negacef</strong> is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).</p><p>&sect; Nosocomial pneumonia</p><p>&sect; Broncho-pulmonary infections in cystic fibrosis</p><p>&sect; Bacterial meningitis</p><p>&sect; Chronic suppurative otitis media</p><p>&sect; Malignant otitis externa</p><p>&sect; Complicated urinary tract infections</p><p>&sect; Complicated skin and soft tissue infections</p><p>&sect; Complicated intra-abdominal infections</p><p>&sect; Bone and joint infections</p><p>&sect; Peritonitis associated with dialysis in patient on CAPD.</p><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (TURP).</p><p>The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria (see sections 4.4 and 5.1).</p><p>Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.</p><p>Consideration should be given to official guidelines on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong>Table 1: Adults and children &ge; 40 kg</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Intermittent Administration</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose to be administered</strong></p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>100 to 150 mg/kg/day every 8 h, maximum 9 g per day<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td rowspan="4" style="vertical-align:top"><p>2 g every 8 h</p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top"><p>Bone and joint infections</p></td><td rowspan="4" style="vertical-align:top"><p>1-2 g every 8 h</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients on CAPD</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>1-2 g every 8 h or 12 h</p></td></tr><tr><td style="vertical-align:top"><p>Per-operative prophylaxis for transurethral resection of prostate (TURP)</p></td><td style="vertical-align:top"><p>1 g at induction of anaesthesia, and a second dose at catheter removal</p></td></tr><tr><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td><td rowspan="2" style="vertical-align:top"><p>1 g to 2 g every 8 h</p></td></tr><tr><td style="vertical-align:top"><p>Malignant otitis externa</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Continuous infusion</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose to be administered</strong></p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td rowspan="9" style="vertical-align:top"><p>Loading dose of 2 g followed by a continuous infusion of 4 to 6 g every 24 h1</p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top"><p>Bone and joint infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients on CAPD</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup>In adults with normal renal function 9 g/day has been used without adverse effects. *When associated with, or suspected to be associated with, any of the infections listed in 4.1.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 2: Children &lt; 40 kg</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p><strong>Infants and toddlers &gt;2 months and children &lt;40 kg</strong></p></td><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Usual dose</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Intermittent Administration</em></strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td rowspan="3" style="vertical-align:top"><p>100-150 mg/kg/day in three divided doses, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Chronic suppurative otitis media</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Malignant otitis externa</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Neutropenic children</p></td><td rowspan="4" style="vertical-align:top"><p>150 mg/kg/day in three divided doses, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bone and joint infections</p></td><td rowspan="4" style="vertical-align:top"><p>100 &ndash; 150 mg/kg/day in three divided doses, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients on CAPD</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Continuous Infusion</em></strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td rowspan="9" style="vertical-align:top"><p>Loading dose of 60-100 mg/kg followed by a continuous infusion 100-200 mg/kg/day, maximum 6 g/day</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bacteraemia*</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bone and joint infections</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Peritonitis associated with dialysis in patients with CAPD</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neonates and infants &le; 2 months</strong></p></td><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Usual dose</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Intermittent Administration</em></strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Most infections</p></td><td style="vertical-align:top"><p>25-60 mg/kg/day in two divided doses<sup>1</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>In neonates and infants &le; 2 months, the serum half-life of ceftazidime can be three to four times that in adults.</p><p>*Where associated with, or suspects to be associated with, any of the infections listed in section 4.1.</p></td></tr></tbody></table><p><strong><u>Paediatric population </u></strong></p><p>The safety and efficacy of ceftazidime administered as continuous infusion to neonates and infants &le; 2 months has not been established.</p><p><strong><u>Elderly</u></strong></p><p>In view of the age related reduced clearance of ceftazidime in elderly patients, the daily dose should not normally exceed 3 g in those over 80 years of age.</p><p><strong><u>Hepatic impairment</u></strong></p><p>Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment. There are no study data in patients with severe hepatic impairment (see also section 5.2). Close clinical monitoring for safety and efficacy is advised.</p><p><strong><u>Renal impairment</u></strong></p><p>Ceftazidime is excreted unchanged by the kidneys. Therefore, in patients with impaired renal function, the dosage should be reduced (see also section 4.4).</p><p>An initial loading dose of 1 g should be given. Maintenance doses should be based on creatinine clearance:</p><p><strong>Table 3: Recommended maintenance doses of ceftazidime in renal impairment &ndash; intermittent infusion</strong></p><p><em>Adults and children &ge; 40 kg</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance</p><p>Ml/min</p></td><td style="vertical-align:top"><p>Approx. serum creatinine</p><p>&micro;mol/l(mg/dl)</p></td><td style="vertical-align:top"><p>Recommended unit dose of ceftazidime</p><p>(g)</p></td><td style="vertical-align:top"><p>Frequency of dosing</p><p>(hourly)</p></td></tr><tr><td style="vertical-align:top"><p>50-31</p></td><td style="vertical-align:top"><p>150-200</p><p>(1.7-2.3)</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>30-16</p></td><td style="vertical-align:top"><p>200-350</p><p>(2.3-4.0)</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>15-6</p></td><td style="vertical-align:top"><p>350-500</p><p>(4.0-5.6)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>&lt;5</p></td><td style="vertical-align:top"><p>&gt;500</p><p>(&gt;5.6)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>48</p></td></tr></tbody></table><p>In patients with severe infections the unit dose should be increased by 50% or the dosing frequency increased. In children the creatinine clearance should be adjusted for body surface area or lean body mass.</p><p><em>Children &lt; 40 kg</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance</p><p>(ml/min)**</p></td><td style="vertical-align:top"><p>Approx. serum creatinine*</p><p>&micro;mol/l (mg/dl)</p></td><td style="vertical-align:top"><p>Recommended individual dose mg/kg body weight</p></td><td style="vertical-align:top"><p>Frequency of dosing</p><p>(hourly)</p></td></tr><tr><td style="vertical-align:top"><p>50-31</p></td><td style="vertical-align:top"><p>150-200</p><p>(1.7-2.3)</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>30-16</p></td><td style="vertical-align:top"><p>200-350</p><p>(2.3-4.0)</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>15-6</p></td><td style="vertical-align:top"><p>350-500</p><p>(4.0-5.6)</p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>&lt;5</p></td><td style="vertical-align:top"><p>&gt;500</p><p>(&gt;5.6)</p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>48</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* The serum creatinine values are guideline values that may not indicate exactly the same degree of reduction for all patients with reduced renal function.</p><p>** Estimated based on body surface area, or measured.</p></td></tr></tbody></table><p>Close clinical monitoring for safety and efficacy is advised.</p><p><strong><u>Table 4: Recommended maintenance doses of ceftazidime in renal impairment &ndash; continuous infusion</u></strong></p><p><em>Adults and children &ge; 40 kg</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance (ml/min)</p></td><td style="vertical-align:top"><p>Approx. Serum creatinine &micro;mol/l (mg/dl)</p></td><td style="vertical-align:top"><p>Frequency of dosing (hourly)</p></td></tr><tr><td style="vertical-align:top"><p>50-31</p></td><td style="vertical-align:top"><p>150-200</p><p>(1.7-2.3)</p></td><td style="vertical-align:top"><p>Loading dose of 2 g followed by 1 g to 3 g /24 hours</p></td></tr><tr><td style="vertical-align:top"><p>30-16</p></td><td style="vertical-align:top"><p>200-350</p><p>(2.3-4.0)</p></td><td style="vertical-align:top"><p>Loading dose of 2 g followed by 1 g /24 hours</p></td></tr><tr><td style="vertical-align:top"><p>&le; 15</p></td><td style="vertical-align:top"><p>&gt; 350</p><p>(&gt;4.0)</p></td><td style="vertical-align:top"><p>Not evaluated</p></td></tr></tbody></table><p>Caution is advised in dose selection. Close clinical monitoring for safety and efficacy is advised.</p><p><em>Children &lt; 40 kg</em></p><p>The safety and effectiveness of ceftazidime administered as continuous infusion in renally impaired children &lt; 40 kg has not been established, close clinical monitoring for safety and efficacy is advised.</p><p>If continuous infusion is used in children with renal impairment, the creatinine clearance should be adjusted for body surface area or lean body mass.</p><p><strong><u>Haemodialysis</u></strong></p><p>The serum half-life during haemodialysis ranges from 3 to 5 h.</p><p>Following each haemodialysis period, the maintenance dose of ceftazidime recommended in the tables 5 &amp; 6 should be repeated.</p><p><strong><u>Peritoneal dialysis</u></strong></p><p>Ceftazidime may be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD).</p><p>In addition to intravenous use, ceftazidime can be incorporated into the dialysis fluid (usually 125 to 250mg for 2 litres of dialysis solution).</p><p>For patients in renal failure on continuous arterio-venous haemodialysis or high-flux haemofiltration in intensive therapy units: 1 g daily either as a single dose or in divided doses. For low-flux haemofiltration, follow the dose recommended under renal impairment.</p><p>For patients on veno-venous haemofiltration and veno-venous haemodialysis, follow the dosage recommendations in tables 5 &amp; 6 below.</p><p><strong><u>Table 5: Continuous veno-venous haemofiltration dose guidelines</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Residual renal function (creatinine clearance ml/min)</p></td><td colspan="4" style="vertical-align:top"><p>Maintenance dose (mg) for an ultrafiltration rate (ml/min) of<sup>1</sup>:</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>33.3</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1&nbsp;</sup>Maintenance dose to be administered every 12 h.</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Table 6: Continuous veno-venous haemodialysis dose guidelines</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td rowspan="4" style="vertical-align:top"><p><u>Residual renal function (creatinine clearance in ml/min)</u></p></td><td colspan="6" style="vertical-align:top"><p><u>Maintenance dose (mg) for a dialysate in flow rate of&nbsp;<sup>1</sup><sub>:</sub></u></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>1.0 litre/h</u></p></td><td colspan="3" style="vertical-align:top"><p><u>2.0 litre/h</u></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Ultrafiltration rate (litre/h)</u></p></td><td colspan="3" style="vertical-align:top"><p><u>Ultrafiltration rate (litre/h)</u></p></td></tr><tr><td style="vertical-align:top"><p><u>0.5</u></p></td><td style="vertical-align:top"><p><u>1.0</u></p></td><td style="vertical-align:top"><p><u>2.0</u></p></td><td style="vertical-align:top"><p><u>0.5</u></p></td><td style="vertical-align:top"><p><u>1.0</u></p></td><td style="vertical-align:top"><p><u>2.0</u></p></td></tr><tr><td style="vertical-align:top"><p><u>0</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td></tr><tr><td style="vertical-align:top"><p><u>5</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td></tr><tr><td style="vertical-align:top"><p><u>10</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td></tr><tr><td style="vertical-align:top"><p><u>15</u></p></td><td style="vertical-align:top"><p><u>500</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td></tr><tr><td style="vertical-align:top"><p><u>20</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>750</u></p></td><td style="vertical-align:top"><p><u>1000</u></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><u><sup>1</sup></u><u>Maintenance dose to be administered every 12 h.</u></p></td></tr></tbody></table><p><strong><u>Method of administration</u></strong></p><p>The dose depends on the severity, susceptibility, site and type of infection and on the age and renal function of the patient.</p><p><strong>Negacef </strong>1g should be administered by intravenous injection or infusion, or by deep intramuscular injection. Recommended intramuscular injection sites are the upper outer quadrant of the&nbsp;<em>gluteus maximus</em>&nbsp;or lateral part of the thigh. <strong>Negacef </strong>solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. The standard recommended route of administration is by intravenous intermittent injection or intravenous continuous infusion. Intramuscular administration should only be considered when the intravenous route is not possible or less appropriate for the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to ceftazidime, to any other cephalosporin or to any of the excipients listed in section 6.1.
	History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Hypersensitivity</u></strong></p><p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with ceftazidime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftazidime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p><strong><u>Spectrum of activity</u></strong></p><p>Ceftazidime has a limited spectrum of antibacterial activity. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a very high suspicion that the most likely pathogen(s) would be suitable for treatment with ceftazidime. This particularly applies when considering the treatment of patients with bacteraemia and when treating bacterial meningitis, skin and soft tissue infections and bone and joint infections. In addition, ceftazidime is susceptible to hydrolysis by several of the extended spectrum beta lactamases (ESBLs). Therefore information on the prevalence of ESBL producing organisms should be taken into account when selecting ceftazidime for treatment.</p><p><strong><u>Pseudomembranous colitis</u></strong></p><p>Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all anti-bacterial agents, including ceftazidime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftazidime (see section 4.8). Discontinuation of therapy with ceftazidime and the administration of specific treatment for&nbsp;<em>Clostridium difficile&nbsp;</em>should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p><strong><u>Renal function</u></strong></p><p>Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function.</p><p>Ceftazidime is eliminated via the kidneys; therefore the dose should be reduced according to the degree of renal impairment. Patients with renal impairment should be closely monitored for both safety and efficacy. Neurological sequelae have occasionally been reported when the dose has not been reduced in patients with renal impairment (see section 4.2 and 4.8).</p><p><strong><u>Overgrowth of non-susceptible organisms</u></strong></p><p>Prolonged use may result in the overgrowth of non-susceptible organisms (e.g. Enterococci, fungi) which may require interruption of treatment or other appropriate measures. Repeated evaluation of the patient&#39;s condition is essential.</p><p><strong><u>Test and assay interactions</u></strong></p><p>Ceftazidime does not interfere with enzyme-based tests for glycosuria, but slight interference (false-positive) may occur with copper reduction methods (Benedict&#39;s, Fehling&#39;s, Clinitest).</p><p>Ceftazidime does not interfere in the alkaline picrate assay for creatinine.</p><p>The development of a positive Coombs&#39; test associated with the use of ceftazidime in about 5% of patients may interfere with the cross-matching of blood.</p><p><strong><u>Important information about the ingredients of Negacef:</u></strong></p><p><strong>Negacef</strong> 1g contains 121mg of sodium carbonate per vial.</p><p>This should be considered for patients who are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been conducted with a probenecid and furosemide.</p><p>Concurrent use of high doses with nephrotoxic medicinal products may adversely affect renal function (see section 4.4).</p><p>Chloramphenicol is antagonistic&nbsp;<em>in vitro</em>&nbsp;with ceftazidime and other cephalosporins. The clinical relevance of this finding is unknown, but if concurrent administration of ceftazidime with chloramphenicol is proposed, the possibility of antagonism should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>There are limited amounts of data from the use of ceftazidime in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>Ceftazidime should be prescribed to pregnant women only if the benefit outweighs the risk.</p><p><strong><u>Breast-feeding</u></strong></p><p>Ceftazidime is excreted in human milk in small quantities but at therapeutic doses of ceftazidime no effects on the breast-fed infant are anticipated. Ceftazidime can be used during breast-feeding.</p><p><strong><u>Fertility</u></strong></p><p>No data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions are eosinphilia, thrombocytosis, phlebitis or thrombophlebitis with intravenous administration, diarrhoea, transient increases in hepatic enzymes, maculopapular or uticarcial rash, pain and/or inflammation following intramuscular injection and positive Coomb&#39;s test.</p><p>Data from sponsored and unsponsored clinical trials have been used to determine the frequency of common and uncommon undesirable effects. The frequencies assigned to all other undesirable effects were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following convention has been used for the classification of frequency:</p><p>&sect; Very common &ge;1/10</p><p>&sect; Common &ge;1/100 and &lt;1/10</p><p>&sect; Uncommon &ge;1/1,000 and &lt;1/100</p><p>&sect; Rare &ge;1/10,000 and &lt;1/1000</p><p>&sect; Very rare &lt;1/10,000</p><p>&sect; Unknown (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p><strong><u>System Organ Class</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Very rare</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Unknown</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Infections and infestations</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Candidiasis (including vaginitis and oral thrush)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td><td style="vertical-align:top"><p>Eosinophilia</p><p>Thrombocytosis</p></td><td style="vertical-align:top"><p>Neutropenia</p><p>Leucopenia</p><p>Thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Agranulocytosis</p><p>Haemolytic anaemia</p><p>Lymphocytosis</p></td></tr><tr><td style="vertical-align:top"><p><u>Immune system disorders</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylaxis (including bronchospasm and/or hypotension) (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><u>Nervous system disorders</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Neurological sequelae<sup>1</sup></p><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p><u>Vascular disorders</u></p></td><td style="vertical-align:top"><p>Phlebitis or thrombophlebitis with intravenous administration</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Antibacterial agent-associated diarrhoea and colitis<sup>2</sup>&nbsp;(see section 4.4)</p><p>Abdominal pain</p><p>Nausea</p><p>Vomiting</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bad taste</p></td></tr><tr><td style="vertical-align:top"><p><u>Heptobiliary disorders</u></p></td><td style="vertical-align:top"><p>Transient elevations in one or more hepatic enzymes<sup>3</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td><td style="vertical-align:top"><p>Maculopapular or urticarial rash</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p><p>Stevens-Johnson syndrome</p><p>Erythema multiforme</p><p>Angioedema</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Transient elevations of blood urea, blood urea nitrogen and/or serum creatinine</p></td><td style="vertical-align:top"><p>Interstitial nephritis</p><p>Acute renal failure</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td><td style="vertical-align:top"><p>Pain and/or inflammation after intramuscular injection</p></td><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><u>Investigations</u></p></td><td style="vertical-align:top"><p>Positive Coombs&#39; test<sup>5</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>1</sup>There have been reports of neurological sequelae including tremor, myoclonia, convulsions, encephalopathy and coma in patients with renal impairment in whom the dose of ceftazidime has not been appropriately reduced.</p><p><sup>2</sup>Diarrhoea and colitis may be associated with&nbsp;<em>Clostridium difficile</em>&nbsp;and may present as pseudomembranous colitis.</p><p><sup>3</sup>ALT (SGPT), AST (SOGT), LHD, GGT, alkaline phosphatase.</p><p><sup>4</sup>There have been rare reports where DRESS has been associated with ceftazidime.</p><p><sup>5</sup>A positive Coombs test develops in about 5% of patients and may interfere with blood cross matching.</p><p>&nbsp;</p><p><strong><u>To report any side effect(s):</u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Center (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma.</p><p>Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4)</p><p>Serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Anti-bacterials for systemic use.</p><p>Third-generation cephalosporins ATC code: J01DD02</p><p><strong><u>Mechanism of action</u></strong></p><p>Ceftazidime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p><strong><u>PK/PD relationship</u></strong></p><p>For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with&nbsp;<em>in vivo</em>&nbsp;efficacy has been shown to be the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftazidime for individual target species (i.e. %T&gt;MIC).</p><p><strong><u>Mechanism of Resistance</u></strong></p><p>Bacterial resistance to ceftazidime may be due to one or more of the following mechanisms:</p><p>&sect; hydrolysis by beta-lactamases. Ceftazidime may be efficiently hydrolysed by extended-spectrum beta-lactamases (ESBLs), including the SHV family of ESBLs and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species</p><p>&sect; reduced affinity of penicillin-binding proteins for ceftazidime</p><p>&sect; outer membrane impermeability, which restricts access of ceftazidime to penicillin binding proteins in Gram-negative organisms</p><p>&sect; bacterial efflux pumps.</p><p><strong><u>Breakpoints</u></strong></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p>Organism</p></td><td colspan="3" style="vertical-align:top"><p>Breakpoints (mg/L)</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>S</p></td><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>R</p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriaceae</p></td><td style="vertical-align:top"><p>&le;1</p></td><td style="vertical-align:top"><p>2-4</p></td><td style="vertical-align:top"><p>&gt;4</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td><td style="vertical-align:top"><p>&le;8<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p><em>Non-species related breakpoints<sup>2</sup></em></p></td><td style="vertical-align:top"><p>&le;4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr></tbody></table><p>S=Susceptible, I=Intermediate, R=Resistant</p><p><sup>1</sup>The breakpoints relate to high dose therapy (2 g x 3).</p><p><sup>2</sup>Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species not mentioned in the table or footnotes.</p><p><strong><em><u>Microbiological Susceptibility</u></em></strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftazidime in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly Susceptible Species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Streptococcus pyogenes</em></p><p><em>Streptococcus agalactiae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Citrobacter koseri</em></p><p><em>Haemophilus influenzae</em></p><p><em>Moraxella catarrhalis</em></p><p><em>Neisseria menigitidis</em></p><p><em>Pasteurella multocida</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus spp&nbsp;</em>(other)</p><p><em>Providencia</em>&nbsp;spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Acinetobacter baumannii<sup>+</sup></em></p><p><em>Burkholderia cepacia</em></p><p><em>Citrobacter freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Klebsiella spp (other)</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Serratia spp</em></p><p><em>Morganella morganii</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Staphylococcus aureus&pound;</em></p><p><em>Staphylococcus pneumoniae<sup>&pound;&pound;</sup></em></p><p><em>Viridans group streptococcus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Clostridium perfringens</em></p><p><em>Peptostreptococcus spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes</u></p><p><em>Fusobacterium spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p>Enterococcus spp including<em>&nbsp;Enterococcus faecalis&nbsp;</em>and&nbsp;<em>Enterococcus faecium</em></p><p><em>Listeria spp</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes</u></p><p><em>Bacteroides</em>&nbsp;spp. (many strains of&nbsp;<em>Bacteroides fragilis</em>&nbsp;are resistant).</p></td></tr><tr><td style="vertical-align:top"><p><u>Others:</u></p><p><em>Chlamydia&nbsp;</em>spp</p><p><em>Mycoplasma</em>&nbsp;spp</p><p><em>Legionella</em>&nbsp;spp</p></td></tr><tr><td style="vertical-align:top"><p><sup>&pound;</sup>S.<em>aureus</em>&nbsp;that is methicillin susceptible are considered to have inherent low susceptibility to ceftazidime.All methicillin-resistance&nbsp;<em>S. Aureus</em>&nbsp;are resistant to ceftazidime.</p><p><sup>&pound;&pound;</sup>S.pneumoniae that demonstrate intermediate susceptibility or are resistant to penicillin can be expected to demonstrate at least reduced susceptibility to ceftazidime.</p><p>+High rates of resistance have been observed in one or more areas/countries/regions within the EU.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>After intramuscular administration of 500 mg and 1 g of ceftazidime, peak plasma levels of 18 and 37 mg/l respectively are achieved rapidly. Five minutes after intravenous bolus injection of 500 mg, 1 g or 2 g, plasma levels are 46, 87 and 170mg/l, respectively. The kinetics of ceftazidime are linear within the single dose range of 0.5 to 2 g following intravenous or intramuscular dosing.</p><p><strong><u>Distribution</u></strong></p><p>The serum protein binding of ceftazidime is low at about 10%. Concentrations in excess of the MIC for common pathogens can be achieved in tissues such as bone, heart, bile, sputum, aqueous humour, synovial, pleural and peritoneal fluids. Ceftazidime crosses the placenta readily, and is excreted in the breast milk. Penetration of the intact blood-brain barrier is poor, resulting in low levels of ceftazidime in the CSF in the absence of inflammation. However, concentrations of 4 to 20 mg/l or more are achieved in the CSF when the meninges are inflamed.</p><p><strong><u>Biotransformation</u></strong></p><p>Ceftazidime is not metabolised.</p><p><strong><u>Elimination</u></strong></p><p>After parenteral administration plasma levels decrease with a half-life of about 2 h. Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80 to 90 % of the dose is recovered in the urine within 24 h. Less than 1 % is excreted via the bile.</p><p><strong><u>Special patient populations</u></strong></p><p><strong>Renal impairment</strong></p><p>Elimination of ceftazidime is decreased in patients with impaired renal function and the dose should be reduced (see section 4.2).</p><p><strong>Hepatic impairment</strong></p><p>The presence of mild to moderate hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days provided renal function was not impaired (see section 4.2).</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>The reduced clearance observed in elderly patients was primarily due to age-related decrease in renal clearance of ceftazidime. The mean elimination half-life ranged from 3.5 to 4 hours following single or 7 days repeat BID dosing of 2 g IV bolus injections in elderly patients 80 years or older.</p><p><strong>Paediatric population</strong></p><p>The half-life of ceftazidime is prolonged in preterm and term neonates by 4.5 to 7.5 hours after doses of 25 to 30 mg/kg. However, by the age of 2 months the half-life is within the range for adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeat dose toxicity, genotoxicity, toxicity to reproduction. Carcinogenicity studies have not been performed with ceftazidime.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Inactive Ingredients:</u></strong></p><ol><li>Sodium Carbonate</li></ol>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftazidime is less stable in Sodium Bicarbonate Injection than in other intravenous fluids. It is not recommended as a diluent. Ceftazidime and aminoglycosides should not be mixed in the same giving set or syringe. Precipitation has been reported with vancomycin added to ceftazidime in solution. Therefore, it would be prudent to flush giving sets and intravenous lines between administration of these two agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Un-opened vials: 24 months from the date of manufacturing
Opened vials: see “Stability after reconstitution” in section 6.6.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Before reconstitution</strong>, store below 30&deg;C. Protect from light and heat.</p><p><strong>After reconstitution, see &ldquo;</strong><strong>Stability after reconstitution&rdquo; in section 6.6. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear glass vial with a printed label, one vial packed in a printed box along with a leaflet.</p><p>Clear glass vial with a printed label, 10 vials packed in a printed box along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Instructions for Use/Handling</u></strong></p><p>All sizes of vials of <strong>Negacef</strong> Injection are supplied under reduced pressure. As the product dissolves, carbon dioxide is released and a positive pressure develops. Small bubbles of carbon dioxide in the constituted solution may be ignored.</p><p>See the following table for different volumes and solution concentrations, which may be useful when fractional doses are required.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:668px"><tbody><tr><td colspan="2"><p><strong>Vial size</strong></p></td><td><p><strong>Amount of diluents</strong></p><p><strong>to be added (ml)</strong></p></td><td><p><strong>Approximate concentration (mg/ml)</strong></p></td></tr><tr><td colspan="4"><p>1g powder for solution for injection</p></td></tr><tr><td><p>1g</p></td><td><p>Intramuscular</p><p>Intravenous bolus</p><p>Intravenous infusion</p></td><td style="vertical-align:top"><p>3ml</p><p>10ml</p><p>50ml*</p></td><td style="vertical-align:top"><p>260</p><p>90</p><p>20</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*NOTE: Addition should be in two stages</p><p>Solutions range from light yellow to yellow depending on concentration, diluent and storage conditions used. Within the stated recommendations, product potency is not adversely affected by such colour variations.</p><p>&sect; Ceftazidime at concentrations between 1mg/ml and 40mg/ml is compatible with:</p><p>-&nbsp;&nbsp;&nbsp; Sodium Chloride 9mg/ml (0.9%) solution for injection</p><p>-&nbsp;&nbsp;&nbsp; M/6 Sodium Lactate Injection</p><p>-&nbsp;&nbsp;&nbsp; Compound Sodium Lactate Injection (Hartmann&rsquo;s Solution)</p><p>-&nbsp;&nbsp;&nbsp; 5% Dextrose Injection</p><p>-&nbsp;&nbsp;&nbsp; 0.225% Sodium Chloride and 5% Dextrose Injection</p><p>-&nbsp;&nbsp;&nbsp; 0.45% Sodium Chloride and 5% Dextrose Injection</p><p>-&nbsp;&nbsp;&nbsp; 0.9% Sodium Chloride and 5% Dextrose Injection</p><p>-&nbsp;&nbsp;&nbsp; 0.18% Sodium Chloride and 4% Dextrose Injection</p><p>-&nbsp;&nbsp;&nbsp; 10% Dextrose Injection</p><p>-&nbsp;&nbsp;&nbsp; Dextran 40 Injection 10% in 0.9% Sodium Chloride Injection</p><p>-&nbsp;&nbsp;&nbsp; Dextran 40 Injection 10% in 5% Dextrose Injection</p><p>-&nbsp;&nbsp;&nbsp; Dextran 70 Injection 6% in 0.9% Sodium Chloride Injection</p><p>-&nbsp;&nbsp;&nbsp; Dextran 70 Injection 6% in 5% Dextrose Injection.</p><p>&sect; Ceftazidime at concentrations between 0.05mg/ml and 0.25mg/ml is compatible with Intra-peritoneal Dialysis Fluid (Lactate).</p><p>&sect; Ceftazidime<strong> </strong>may be constituted for i.m. use with 0.5% or 1% Lidocaine Hydrochloride Injection.<strong> </strong><strong>Solutions in lidocaine must never be administered intravenously.</strong></p><p><strong><u>Preparation of solution for bolus injection</u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe needle through the vial closure and inject the recommended volume of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake to dissolve: carbon dioxide is released and a clear solution will be obtained in about 1 to 2 minutes.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert the vial. With the syringe plunger fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the head space. The withdrawn solution may contain small bubbles of carbon dioxide; they may be disregarded.</p><p>These solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. Ceftazidime is compatible with the most commonly used intravenous fluids.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong><u>Stability after reconstitution</u></strong></p><p>In keeping with good pharmaceutical practice, it is preferable to use freshly constituted solutions of <strong>Negacef</strong> for injection. If this is not practicable, satisfactory potency is retained for 24 hours in the refrigerator (2 - 8&deg;C) when prepared in Water for Injection BP or any of the injections listed above.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10. January .2018	
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>